234 related articles for article (PubMed ID: 31271873)
1. Toll-like receptors and their therapeutic potential in Parkinson's disease and α-synucleinopathies.
Kouli A; Horne CB; Williams-Gray CH
Brain Behav Immun; 2019 Oct; 81():41-51. PubMed ID: 31271873
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammation and protein pathology in Parkinson's disease dementia.
Kouli A; Camacho M; Allinson K; Williams-Gray CH
Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
[TBL] [Abstract][Full Text] [Related]
4. Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells.
Kim C; Kwon S; Iba M; Spencer B; Rockenstein E; Mante M; Adame A; Shin SJ; Fields JA; Rissman RA; Lee SJ; Masliah E
Exp Mol Med; 2021 Feb; 53(2):281-290. PubMed ID: 33594256
[TBL] [Abstract][Full Text] [Related]
5. The role of Toll-like receptors and neuroinflammation in Parkinson's disease.
Heidari A; Yazdanpanah N; Rezaei N
J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422
[TBL] [Abstract][Full Text] [Related]
6. How Toll-like receptors influence Parkinson's disease in the microbiome-gut-brain axis.
Zhang Z; Liu Z; Lv A; Fan C
Front Immunol; 2023; 14():1154626. PubMed ID: 37207228
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology.
Dzamko N; Gysbers A; Perera G; Bahar A; Shankar A; Gao J; Fu Y; Halliday GM
Acta Neuropathol; 2017 Feb; 133(2):303-319. PubMed ID: 27888296
[TBL] [Abstract][Full Text] [Related]
8. TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut.
Gorecki AM; Anyaegbu CC; Anderton RS
Transl Neurodegener; 2021 Nov; 10(1):47. PubMed ID: 34814947
[TBL] [Abstract][Full Text] [Related]
9. Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2.
Xia Y; Zhang G; Kou L; Yin S; Han C; Hu J; Wan F; Sun Y; Wu J; Li Y; Huang J; Xiong N; Zhang Z; Wang T
Brain; 2021 Aug; 144(7):2024-2037. PubMed ID: 33792662
[TBL] [Abstract][Full Text] [Related]
10. Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.
Béraud D; Maguire-Zeiss KA
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1(0 1):S17-20. PubMed ID: 22166424
[TBL] [Abstract][Full Text] [Related]
11. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
[TBL] [Abstract][Full Text] [Related]
12. MerTK is a mediator of alpha-synuclein fibril uptake by human microglia.
Dorion MF; Yaqubi M; Senkevich K; Kieran NW; MacDonald A; Chen CXQ; Luo W; Wallis A; Shlaifer I; Hall JA; Dudley RWR; Glass IA; ; Stratton JA; Fon EA; Bartels T; Antel JP; Gan-Or Z; Durcan TM; Healy LM
Brain; 2024 Feb; 147(2):427-443. PubMed ID: 37671615
[TBL] [Abstract][Full Text] [Related]
13. The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration.
Rosenberger K; Derkow K; Dembny P; Krüger C; Schott E; Lehnardt S
J Neuroinflammation; 2014 Sep; 11():166. PubMed ID: 25239168
[TBL] [Abstract][Full Text] [Related]
14. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.
Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T
Front Immunol; 2021; 12():719807. PubMed ID: 34691027
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy.
Venezia S; Refolo V; Polissidis A; Stefanis L; Wenning GK; Stefanova N
Mol Neurodegener; 2017 Jul; 12(1):52. PubMed ID: 28676095
[TBL] [Abstract][Full Text] [Related]
16. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.
Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM
Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483
[TBL] [Abstract][Full Text] [Related]
17. Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.
Caplan IF; Maguire-Zeiss KA
Front Pharmacol; 2018; 9():417. PubMed ID: 29780321
[TBL] [Abstract][Full Text] [Related]
18. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
19. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
[TBL] [Abstract][Full Text] [Related]
20. Gut-to-brain spreading of pathology in synucleinopathies: A focus on molecular signalling mediators.
Schmitt V; Masanetz RK; Weidenfeller M; Ebbinghaus LS; Süß P; Rosshart SP; von Hörsten S; Zunke F; Winkler J; Xiang W
Behav Brain Res; 2023 Aug; 452():114574. PubMed ID: 37423320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
